表紙
市場調查報告書

化療誘發性嗜中性白血球低下症治療藥的全球市場:2018年∼2022年

Global Chemotherapy-induced Neutropenia Therapeutics Market 2018-2022

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 650398
出版日期 內容資訊 英文 102 Pages
訂單完成後即時交付
價格
化療誘發性嗜中性白血球低下症治療藥的全球市場:2018年∼2022年 Global Chemotherapy-induced Neutropenia Therapeutics Market 2018-2022
出版日期: 2018年05月15日內容資訊: 英文 102 Pages
簡介

關於化療誘發性嗜中性白血球低下症治療藥

嗜中性白血球是免疫誘導性的白血球。該數的減少引起嗜中性白血球低下症。治療中化療引起的嗜中性白血球低下症發生的話,患者的感染風險高漲,癌症治療被中斷。

Technavio的分析師預測,從2018年到2022年,全球化療誘發性嗜中性白血球低下症治療藥市場將以5.52%的年複合成長率成長。

本報告提供全球化療誘發性嗜中性白血球低下症治療藥市場相關調查分析,市場規模與成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,主要供應商等相關的系統性資訊。

目錄

第1章 摘要整理

第2章 調查範圍

第3章 調查方法

第4章 市場情形

  • 市場生態系統
  • 市場特性
  • 市場區隔分析

第5章 市場規模

  • 市場定義
  • 市場規模(2017年)
  • 市場規模及預測(2017-2022年)

第6章 波特的五力分析

  • 買主談判力
  • 供應商談判力
  • 新加入廠商的威脅
  • 替代品的威脅
  • 競爭對手的威脅
  • 市場情形

第7章 市場區隔:治療

  • 市場區隔:各治療(2017-2022年)
  • 比較:各治療
  • G-CSF療法 - 市場規模與預測
  • 顆粒球輸血 - 市場規模與預測
  • 抗生素治療 - 市場規模與預測
  • 脾臟摘出 - 市場規模與預測
  • 市場機會:各治療

第8章 客戶形勢

第9章 地區形勢

  • 各地區市場區隔(2017-2022年)
  • 地區比較
  • 南北美洲 - 市場規模與預測
  • 歐洲、中東、非洲地區 - 市場規模與預測
  • 亞太地區 - 市場規模與預測
  • 主要國家
  • 市場機會

第10章 決策架構

第11章 成長要素與課題

  • 市場成長要素
  • 市場課題

第12章 市場趨勢

  • 癌症治療相關全球性認識的高漲
  • 技術的進步
  • 策略性聯盟

第13章 業者情勢

  • 概要
  • 創造性破壞狀況

第14章 供應商分析

  • 交易廠商
  • 供應商分類
  • 供應商的市場定位
  • Amgen
  • Intas Pharmaceuticals
  • Novartis
  • Partner Therapeutics
  • Teva Pharmaceuticals Industries

第15章 附錄

  • 簡稱的清單
目錄
Product Code: IRTNTR22916

About Chemotherapy-induced Neutropenia Therapeutics

Neutrophils are immunity-inducing white blood cells. Reduction in its number causes neutropenia. Chemotherapy-induced neutropenia occurring during treatment increases patient's risk of infection and disrupts cancer treatment.

Technavio's analysts forecast the Global Chemotherapy-Induced Neutropenia Therapeutics Market to grow at a CAGR of 5.52% during the period 2018-2022.

Covered in this report

The report covers the present scenario and the growth prospects of the global chemotherapy-induced neutropenia therapeutics market. To calculate the market size, the report considers the revenue generated from the adoption of CIN treatment.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Chemotherapy-induced Neutropenia Therapeutics Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Amgen
  • Intas Pharmaceuticals
  • Novartis
  • Partner Therapeutics
  • Teva Pharmaceuticals Industries

Market driver

  • Rapid development in molecular oncology
  • For a full, detailed list, view our report

Market challenge

  • Lack of accessibility and affordability of cancer therapy in developing countries
  • For a full, detailed list, view our report

Market trend

  • Technological advancements
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2022 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 05: MARKET SIZING

  • Market definition
  • Market sizing 2017
  • Market size and forecast 2017-2022

PART 06: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 07: MARKET SEGMENTATION BY PROCEDURE

  • Segmentation by procedure
  • Comparison by procedure
  • G-CSF therapy - Market size and forecast 2017-2022
  • Granulocyte transfusion - Market size and forecast 2017-2022
  • Antibiotic therapy - Market size and forecast 2017-2022
  • Splenectomy - Market size and forecast 2017-2022
  • Market opportunity by procedure

PART 08: CUSTOMER LANDSCAPE

PART 09: REGIONAL LANDSCAPE

  • Geographical segmentation
  • Regional comparison
  • Americas - Market size and forecast 2017-2022
  • EMEA - Market size and forecast 2017-2022
  • APAC - Market size and forecast 2017-2022
  • Key leading countries
  • Market opportunity

PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 12: MARKET TRENDS

  • Increase in global awareness about cancer treatments
  • Technological advancements
  • Strategic alliances

PART 13: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 14: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Amgen
  • Intas Pharmaceuticals
  • Novartis
  • Partner Therapeutics
  • Teva Pharmaceuticals Industries

PART 15: APPENDIX

  • List of abbreviations

List of Exhibits

  • Exhibit 01: Related market
  • Exhibit 02: Market characteristics
  • Exhibit 03: Market segments
  • Exhibit 04: Market definition - Inclusions and exclusions checklist
  • Exhibit 05: Market size 2017
  • Exhibit 06: Validation techniques employed for market sizing 2017
  • Exhibit 07: Global - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 08: Global - Year-over-year growth 2018-2022 (%)
  • Exhibit 09: Five forces analysis 2017
  • Exhibit 10: Five forces analysis 2022
  • Exhibit 11: Bargaining power of buyers
  • Exhibit 12: Bargaining power of suppliers
  • Exhibit 13: Threat of new entrants
  • Exhibit 14: Threat of substitutes
  • Exhibit 15: Threat of rivalry
  • Exhibit 16: Market condition - Five forces 2017
  • Exhibit 17: Procedure - Market share 2017-2022 (%)
  • Exhibit 18: Comparison by procedure
  • Exhibit 19: G-CSF therapy - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 20: G-CSF therapy - Year-over-year growth 2018-2022 (%)
  • Exhibit 21: Granulocyte transfusion - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 22: Granulocyte transfusion - Year-over-year growth 2018-2022 (%)
  • Exhibit 23: Antibiotic therapy - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 24: Antibiotic therapy - Year-over-year growth 2018-2022 (%)
  • Exhibit 25: Splenectomy - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 26: Splenectomy - Year-over-year growth 2018-2022 (%)
  • Exhibit 27: Market opportunity by procedure
  • Exhibit 28: Customer landscape
  • Exhibit 29: Global - Market share by geography 2017-2022 (%)
  • Exhibit 30: Regional comparison
  • Exhibit 31: Americas - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 32: Americas - Year-over-year growth 2018-2022 (%)
  • Exhibit 33: EMEA - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 34: EMEA - Year-over-year growth 2018-2022 (%)
  • Exhibit 35: APAC - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 36: APAC - Year-over-year growth 2018-2022 (%)
  • Exhibit 37: Key leading countries
  • Exhibit 38: Market opportunity
  • Exhibit 39: R&D funding for cancer for FY2013 to FY2016 ($ millions)
  • Exhibit 40: Vendor landscape
  • Exhibit 41: Landscape disruption
  • Exhibit 42: Vendor classification
  • Exhibit 43: Market positioning of vendors
  • Exhibit 44: Amgen overview
  • Exhibit 45: Amgen - Business segments
  • Exhibit 46: Amgen - Organizational developments
  • Exhibit 47: Amgen - Geographic focus
  • Exhibit 48: Amgen - Key offerings
  • Exhibit 49: Intas Pharmaceuticals overview
  • Exhibit 50: Intas Pharmaceuticals - Business segments
  • Exhibit 51: Intas Pharmaceuticals - Organizational developments
  • Exhibit 52: Intas Pharmaceuticals - Geographic focus
  • Exhibit 53: Intas Pharmaceuticals - Segment focus
  • Exhibit 54: Intas Pharmaceuticals - Key offerings
  • Exhibit 55: Novartis overview
  • Exhibit 56: Novartis - Business segments
  • Exhibit 57: Novartis - Organizational developments
  • Exhibit 58: Novartis - Geographic focus
  • Exhibit 59: Novartis - Segment focus
  • Exhibit 60: Novartis - Key offerings
  • Exhibit 61: Partner Therapeutics overview
  • Exhibit 62: Partner Therapeutics - Business segments
  • Exhibit 63: Partner Therapeutics - Organizational developments
  • Exhibit 64: Partner Therapeutics - Geographic focus
  • Exhibit 65: Partner Therapeutics - Key offerings
  • Exhibit 66: Teva Pharmaceuticals Industries overview
  • Exhibit 67: Teva Pharmaceuticals Industries - Business segments
  • Exhibit 68: Teva Pharmaceuticals Industries - Organizational developments
  • Exhibit 69: Teva Pharmaceuticals Industries - Geographic focus
  • Exhibit 70: Teva Pharmaceuticals Industries - Segment focus
  • Exhibit 71: Teva Pharmaceuticals Industries - Key offerings